8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 30, 2007

SONTRA MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota	000-23017	41-1649949
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

10 Forge Parkway

Franklin, Massachusetts 02038

(Address of principal executive offices) (Zip Code)

(508) 553-8850

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item  2.02 Results of Operations and Financial Condition.

On March 30, 2007, Sontra Medical Corporation (the “Registrant”) issued a press release regarding its financial results for its fiscal fourth quarter and fiscal year ended December 31, 2006. A copy of the press release issued by the Registrant is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

Item  9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished with this Form 8-K:

99.1Press Release of the Registrant, dated March 30, 2007.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SONTRA MEDICAL CORPORATION
Date: March 30, 2007	By:	/s/ Harry G. Mitchell
		Harry G. Mitchell Interim Chief Executive Officer, Chief Financial Officer and Treasurer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release of the Registrant, dated March 30, 2007.

EX-99.1

Exhibit 99.1

Press Release March 30. 2007

	Investor Relations Contacts:
	Harry G. Mitchell, Interim CEO
	508-530-0311
	hmitchell@sontra.com

FOR IMMEDIATE RELEASE

Sontra Medical Reports Fourth Quarter and Fiscal Year 2006 Results and Business Update

Franklin, MA – March 30, 2007 -- Sontra Medical Corporation (SONT.PK) filed its Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 with the Securities and Exchange Commission yesterday. The Annual Report on Form 10-KSB is now available on the SEC’s website at www.sec.gov. For the three months ended December 31, 2006, the net loss applicable to common stockholders was $1,117,545 or $.38 per share, as compared to $1,186,744 or $.53 per share, for the same period in 2005. For the year ended December 31, 2006, the net loss applicable to common stockholders was $5,346,831, or $1.97 per share, as compared to $5,743,003, or $2.59 per share, in 2005. The Company ended the year with a total of $559,017 in cash and short term investments.

During the last half of 2006, the Company had been working on seeking additional capital; however, the Company was not successful in completing a financing transaction at that time. As previously reported, during the first quarter of fiscal 2007 the Company closed on a $660,000 common stock and warrant financing with Sherbrooke Partners, LLC, certain other accredited investors and certain members of the Company’s board of directors and management team. Proceeds from the financing will be used for working capital purposes. The Company will continue its research and development efforts with its continuous glucose monitoring system and plans to pursue opportunities for partnering in drug delivery as well as transdermal diagnostics.

About Sontra Medical Corporation (www.sontra.com)

Sontra Medical Corporation, a technology leader in transdermal science, is developing a non-invasive, continuous transdermal glucose monitor (“CTGM”) for use in the Diabetes and Intensive Care Markets. In addition, the Company owns the FDA approved SonoPrep^® ultrasound-mediated skin permeation technology, presently used with topical lidocaine to achieve rapid (within five minutes) skin anesthesia. The Company is using its technical competencies in transdermal drug formulation, delivery systems and biosensors to develop a new paradigm in transdermal drug delivery and diagnosis.

^© 2007 Sontra Medical Corporation. SonoPrep is a registered trademark of Sontra Medical Corporation. All other company, product or service names mentioned herein are the trademarks or registered trademarks of their respective owners.

© 2002 – 2007 Sontra Medical Corporation. All rights reserved worldwide.                            - 1 -

Press Release March 30. 2007

# # #

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology, including a continuous transdermal glucose monitor for the Diabetes and hospital ICU market; the expected benefits and efficacy of the SonoPrep device in connection with diagnostics, vaccine delivery, glucose monitoring and transdermal science; the availability of substantial additional funding to continue our operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2006, and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

# # #

10 Forge Parkway
Franklin, MA 02038, USA
Tel: 1+ 877-4-SONTRA (766878)
Fax: 1+ 508-553-8760
www.sontra.com	© 2002 – 2007 Sontra Medical Corporation. All rights reserved worldwide.	- 2 -